최근 3번의 대유행 동안 한국 소아에서 발생한마이코플라즈마 폐렴의 임상적 특징
Clinical characteristics of Mycoplasma pneumoniae pneumonia in Korean children during the recent 3 epidemics
1
조회
0
다운로드
9
인용
0
참고문헌
키워드
초록
Purpose: Mycoplasma pneumoniae (MP) is a major cause of community-acquired pneumonia in children. Since 2000, emerging macrolide-resistant MP has been reported. Three epidemics of MP pneumonia have occurred in Korea during the past 10 years: 2006–2007, 2011, and 2015. We investigated the differences in MP pneumonia of each epidemic in terms of clinical, laboratory, and radiologic perspectives. Methods: We retrospectively analyzed 529 medical records of children (1–18 years of age) who were admitted and diagnosed with MP pneumonia at Kangbuk Samsung Hospital during the past 3 epidemic periods. We compared the clinical, laboratory, and radiologic characteristics of MP pneumonia among individual epidemics and between children younger and older than 6 years of age. Results: The mean age of the patients was 5.7 years old, which had increased by each epidemic and showed the highest (6.3 years old) in 2015 compared to previous epidemics. Among 3 epidemics, there were no sex differences. The duration of fever after admission and hospitalization, and the percentage of lobar pneumonia and use of systemic steroids increased significantly in 2015 epidemic. Since 2006, the mean levels of erythrocyte sedimentation rate and lactate dehydrogenase had increased and in 2015 it marked the highest. Children older than 6 years showed a higher proportion of lobar pneumonia and pleural effusion as well as longer duration of fever (before and after admission) and hospitalization days than those younger than 6 years. Conclusion: This study suggests an increasing incidence of refractory MP pneumonia which required a more frequent use of systemic steroids over the past 10 years, and children older than 6 years were found to have more severe pneumonia than those younger than 6 years.
Abstract
Purpose: Mycoplasma pneumoniae (MP) is a major cause of community-acquired pneumonia in children. Since 2000, emerging macrolide-resistant MP has been reported. Three epidemics of MP pneumonia have occurred in Korea during the past 10 years: 2006–2007, 2011, and 2015. We investigated the differences in MP pneumonia of each epidemic in terms of clinical, laboratory, and radiologic perspectives. Methods: We retrospectively analyzed 529 medical records of children (1–18 years of age) who were admitted and diagnosed with MP pneumonia at Kangbuk Samsung Hospital during the past 3 epidemic periods. We compared the clinical, laboratory, and radiologic characteristics of MP pneumonia among individual epidemics and between children younger and older than 6 years of age. Results: The mean age of the patients was 5.7 years old, which had increased by each epidemic and showed the highest (6.3 years old) in 2015 compared to previous epidemics. Among 3 epidemics, there were no sex differences. The duration of fever after admission and hospitalization, and the percentage of lobar pneumonia and use of systemic steroids increased significantly in 2015 epidemic. Since 2006, the mean levels of erythrocyte sedimentation rate and lactate dehydrogenase had increased and in 2015 it marked the highest. Children older than 6 years showed a higher proportion of lobar pneumonia and pleural effusion as well as longer duration of fever (before and after admission) and hospitalization days than those younger than 6 years. Conclusion: This study suggests an increasing incidence of refractory MP pneumonia which required a more frequent use of systemic steroids over the past 10 years, and children older than 6 years were found to have more severe pneumonia than those younger than 6 years.
참고문헌 (31)
- Waites KB, "Mycoplasma pneumoniae and its role as a human pathogen", Clin Microbiol Rev, 17, pp.697~728 (2004)
- Foy HM, "Long-term epidemiology of infections with Mycoplasma pneumoniae", J Infect Dis, 139, pp.681~687 (1979)
- Hauksdottir GS, "Outbreaks of Mycoplasma pneumoniae infections in Iceland 1987 to 1997: a ten and a half years review", Eur J Epidemiol, 15, pp.95~96 (1999)
- Ito I, "Culturally verified Mycoplasma pneumoniae pneumonia in Japan: a long-term observation from 1979-99", Epidemiol Infect, 127, pp.365~367 (2001)
- Lind K Benzon MW, "A seroepidemiological study of Mycoplasma pneumoniae infections in Denmark over the 50-year period 1946-1995", Eur J Epidemiol, 13, pp.581~586 (1997)
- Pönkä A, "Occurrence of serologically verified Mycoplasma pneumoniae infections in Finland and in Scandinavia in 1970-1977", Scand J Infect Dis, 12, pp.27~31 (1980)
- Rastawicki W, "Occurrence of serologically verified Mycoplasma pneumoniae infections in Poland in 1970-1995", Eur J Epidemiol, 14, pp.37~40 (1998)
- Ma YJ, "Clinical and epidemiological characteristics in children with community-acquired mycoplasma pneumonia in Taiwan: a nationwide surveillance", J Microbiol Immunol Infect, 48, pp.632~638 (2015)
- Sztrymf B, "Mycoplasma-related pneumonia: a rare cause of acute respiratory distress syndrome (ARDS) and of potential antibiotic resistance", Rev Mal Respir, 30, pp.77~80 (2013)
- Wang RS, "Necrotizing pneumonitis caused by Mycoplasma pneumoniae in pediatric patients: report of five cases and review of literature", Pediatr Infect Dis J, 23, pp.564~567 (2004)
- Shen Y, "Combination therapy with immune-modulators and moxifloxacin on fulminant macrolide-resistant Mycoplasma pneumoniae infection: a case report", Pediatr Pulmonol, 48, pp.519~522 (2013)
- Katsushima Y, "Characteristics of Mycoplasma pneumoniae infection identified on culture in a pediatric clinic", Pediatr Int, 57, pp.247~252 (2015)
- Liu Y, "Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China", Antimicrob Agents Chemother, 53, pp.2160~2162 (2009)
- Xin D, "Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China", Antimicrob Agents Chemother, 53, pp.2158~2159 (2009)
- Hong KB, "Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011", Emerg Infect Dis, 19, pp.1281~1284 (2013)
- Hsieh YC, "Life-threatening pneumonia caused by macrolide-resistant Mycoplasmapneumoniae", Pediatr Infect Dis J, 31, pp.208~209 (2012)
- Lee KY, "Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children", Pediatr Pulmonol, 41, pp.263~268 (2006)
- Luo Z, "Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children", Pediatr Pulmonol, 49, pp.377~380 (2014)
- Wang M, "Clinical and laboratory profiles of refractory Mycoplasma pneumoniae pneumonia in children", Int J Infect Dis, 29, pp.18~23 (2014)
- Eun BW, "Mycoplasma pneumoniae in Korean children: the epidemiology of pneumonia over an 18-year period", J Infect, 56, pp.326~331 (2008)
- 김은경, "Epidemiological comparison of three Mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 years", Korean Journal of Pediatrics, 58(5), pp.172~177 (2015), 대한소아과학회
- Kim NH, "Comparison of polymerase chain reaction and the indirect particle agglutination antibody test for the diagnosis of Mycoplasma pneumoniae pneumonia in children during two outbreaks", Pediatr Infect Dis J, 26, pp.897~903 (2007)
- Soo Jin Yoo, "Evaluation of Four Commercial IgG- and IgM-specific EnzymeImmunoassays for Detecting Mycoplasma pneumoniae Antibody:Comparison with Particle Agglutination Assay", Journal of Korean Medical Science, 22(5), pp.795~801 (2007), 대한의학회
- Defilippi A, "Epidemiology and clinical features of Mycoplasma pneumoniae infection in children", Respir Med, 102, pp.1762~1768 (2008)
- Miyashita N, "Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults", J Infect Chemother, 21, pp.153~160 (2015)
- Zhang Y, "The clinical characteristics and predictors of refractory Mycoplasma pneumoniae pneumonia in children", PLoS One, 11, pp.e0156465~ (2016)
- Kawamata R, "Utility of serum ferritin and lactate dehydrogenase as surrogate markers for steroid therapy for Mycoplasma pneumoniae pneumonia", J Infect Chemother, 21, pp.783~789 (2015)
- Seong Hwan Choi, "Serum Vascular Endothelial Growth Factor in Pediatric Patients with Community-Acquired Pneumonia and Pleural Effusion", Journal of Korean Medical Science, 21(4), pp.608~613 (2006), 대한의학회
- Shin JH, "TGF-beta effects on airway smooth muscle cell proliferation, VEGF release and signal transduction pathways", Respirology, 14, pp.347~353 (2009)
- Yamazaki T, "Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae", Front Microbiol, 7, pp.693~ (2016)
- Maroushek SR, "Nelson textbook of pediatrics", pp.1439~1444 (2015), Elsevier